SEC Form 4	
------------	--

Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287								
Estimated average burden									
hours per response:									

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940

			01 00		veounent oor							
1. Name and Address of Reporting Person [*] Kong Garheng				uer Name and Tick is Biopharma		Symbol <u>a, Inc.</u> [XERS]	(Check	ationship of Reporting Person(s) to Issuer k all applicable)				
<u>Itons ournens</u>							~	Director	10% C	Owner		
(Last)	(First)	(Middle)		te of Earliest Transa 5/2024	action (Month/	Day/Year)		Officer (give title below)	Other below)	(specify)		
C/O XERIS BIOPHARMA HOLDINGS, INC.				mendment, Date of	f Original Filed	I (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable					
1375 WEST FULTON STREET, SUITE 1300			0				Line)					
							1	Form filed by On	e Reporting Per	son		
(Street)							Form filed by More than One Reporting Person					
CHICAGO	IL	60607	Rul	e 10b5-1(c)	Transact	ion Indication						
(City)	(State)	(Zip)				action was made pursuant ns of Rule 10b5-1(c). See			en plan that is inte	ended to		
		Table I - Non-	Derivative S	ecurities Acq	uired, Dis	posed of, or Bene	ficially	Owned				
Date			2. Transaction Date Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A Disposed Of (D) (Instr. 3 5)		5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		

			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		. ,
Common Stock	06/05/2024		Α		50,000(1)	Α	\$ <mark>0</mark>	164,144	D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										

			(* 57)**	,	,		,					,		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		Expiration Date (Month/Day/Year) s d			le and unt of rities rlying ative rity (Instr. I 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

Explanation of Responses:

1. These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 5, 2025 or the date of the Company's next annual meeting of stockholders.

Remarks:

/s/ Beth Hecht, as Attorney-in-Dect 06/05/2024

Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.